Lerret Stacee Marie, Garcia-Rodriguez Laura, Skelton Joseph, Biank Vincent, Kilway Denise, Telega Grzegorz
Medical College of Wisconsin, Department of Gastroenterology, Milwaukee, Wisconsin 53226, USA.
Gastroenterol Nurs. 2011 Nov-Dec;34(6):434-7. doi: 10.1097/SGA.0b013e3182371356.
As the prevalence of childhood obesity increases, the incidence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (NASH) also escalates. This study's purpose was to identify the clinical criteria to aid in determining when a liver biopsy is indicated for this growing population because currently no guidelines exist. We performed a retrospective chart review on all patients who were seen in the Nutrition Exercise and Weight Loss Kids™ Program at the Children's Hospital of Wisconsin from July 2003 through December 2004. We analyzed only individuals who underwent liver biopsy with the following criteria: (1) no evidence of other liver disease and (2) aspartate transaminase or alanine aminotransferase greater than 200 IU/L or any elevation of or for more than 6 months. Of the 284 patients reviewed, only eight patients (3%) met the criteria for analysis. Biopsy results demonstrated that 100% had histological evidence of NASH with steatosis, and seven of the eight (87.5%) had NASH with fibrosis, cirrhosis, or both. Obese children with an aspartate transaminase or alanine aminotransferase greater than 200 IU/L or any elevation of aspartate transaminase or alanine aminotransferase for more than 6 months, have a strong likelihood of having NASH with or without fibrosis, cirrhosis, or both.
随着儿童肥胖症患病率的上升,非酒精性脂肪性肝病和非酒精性脂肪性肝炎(NASH)的发病率也在攀升。本研究的目的是确定临床标准,以帮助判断何时应对这一不断增长的人群进行肝活检,因为目前尚无相关指南。我们对2003年7月至2004年12月期间在威斯康星儿童医院的营养、运动与减肥儿童™项目中就诊的所有患者进行了回顾性病历审查。我们仅分析了符合以下标准并接受肝活检的个体:(1)无其他肝病证据;(2)天冬氨酸转氨酶或丙氨酸转氨酶大于200 IU/L,或天冬氨酸转氨酶或丙氨酸转氨酶任何升高持续超过6个月。在审查的284例患者中,只有8例(3%)符合分析标准。活检结果显示,100%有NASH伴脂肪变性的组织学证据,8例中有7例(87.5%)有NASH伴纤维化、肝硬化或两者皆有。天冬氨酸转氨酶或丙氨酸转氨酶大于200 IU/L,或天冬氨酸转氨酶或丙氨酸转氨酶任何升高持续超过6个月的肥胖儿童,很有可能患有伴或不伴纤维化、肝硬化或两者皆有的NASH。